Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27805263 | 0.97 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6740806 | 0.97 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2860749 | 0.95 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL7074989 | 0.92 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL13447235 | 0.92 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2470702 | 0.92 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL545012 | 0.89 | HCAR2 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2921028 | 0.89 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL19130691 | 0.89 | MEN1 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2011531 | 0.89 | MEN1 (0.46) | TAS1R3TAS1R1TAS1R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-111892667-B | Application of fluorine-containing compound modified cationic polymer in preparation of medical cosmetic and health care products | 苏州大学 | 2024-02-20 | — | — | CN | claimed |
| CN-111848832-B | Application of fluorine-containing compound modified cationic polymer as drug carrier and preparation method thereof | 苏州大学 | 2024-02-20 | — | — | CN | claimed |
| CN-111848831-B | Application of fluorine-containing compound modified cationic polymer in preparation of vaccine medicine | 苏州大学 | 2023-06-13 | — | — | CN | claimed |
| EP-4095162-A1 | APPLICATION OF AND PREPARATION METHOD FOR CATIONIC POLYMER MODIFIED BY FLUORINE-CONTAINING COMPOUND AS DRUG CARRIER | Soochow University (CN) | 2022-11-30 | — | — | EP | claimed |
| US-20220273806-A1 | USE OF FLUORINE-CONTAINING COMPOUND-MODIFIED CATIONIC POLYMER AS DRUG CARRIER AND PREPARATION METHOD | SOOCHOW UNIVERSITY (CN) | 2022-09-01 | — | — | US | claimed |
| WO-2021147585-A1 | USE OF CHITOSAN MODIFIED BY FLUORINE-CONTAINING COMPOUND AS DRUG CARRIER AND PREPARATION METHOD THEREFOR | 苏州大学 | 2021-07-29 | — | — | WO | claimed |
| WO-2021147598-A1 | APPLICATION OF AND PREPARATION METHOD FOR CATIONIC POLYMER MODIFIED BY FLUORINE-CONTAINING COMPOUND AS DRUG CARRIER | 苏州大学 | 2021-07-29 | — | — | WO | claimed |
| CN-111892667-A | Application of cationic polymer modified by fluorine-containing compound in preparation of medical beauty and health care products | 苏州大学 | 2020-11-06 | — | — | CN | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273806-A1 | USE OF FLUORINE-CONTAINING COMPOUND-MODIFIED CATIONIC POLYMER AS DRUG CARRIER AND PREPARATION METHOD | F12, SLCO4C1, SLC7A1 | TAS1R3 571/4885TAS1R1 218/4885TAS1R2 423/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | TAS1R3 1889/4885TAS1R1 2623/4885TAS1R2 2330/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | TAS1R3 1031/4885TAS1R1 1032/4885TAS1R2 1178/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | TAS1R3 4440/4885TAS1R1 4355/4885TAS1R2 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.